NEW YORK (GenomeWeb News) – The Debiopharm Group said on Thursday it has inked a one-year collaboration deal with Quartz Bio for support of the biopharmaceutical group’s translational projects.
Quartz Bio, a clinical bioinformatics firm spun out by Merck Serono last September, will provide its expertise in computational analyses and biomarker discovery to Debiopharm’s projects, which are anticipated to range from next-generation sequencing and clinical biomarker data analyses.
"Debiopharm's pioneering biomarker projects are a unique opportunity for Quartz Bio to contribute to the implementation of precision medicine, thus demonstrating that bioinformatics science can bring substantial benefits to patients," Jerome Wojcik, CEO of Swizerland-based Quartz Bio, said in a statement.
Financial and other terms of the deal were not disclosed.